Institute for Precision Cardiovascular Medicine
In 2013, the American Heart Association Board of Directors made a commitment to advance precision cardiovascular medicine. The initial platform launched as the Cardiovascular Genome-Phenome Study (CVGPS) before it evolved into the AHA Institute for Precision Cardiovascular Medicine.
Since 2015, the Institute has established innovative research models, formed strategic collaborations, and enabled patient engagement, data integration and access through state of-the-art technology. Today, the AHA is poised to play a crucial role in helping to deliver on the AHA mission and long-term value proposition.
The Institute is led by an Institute Executive Committee, a highly-diversified team of experts in the fields of genomics, bioinformatics, marketing, and start-up business.